The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts).
K. L. Tedesco
Research Funding - PharmaMar
J. L. Blum
No relevant relationships to disclose
A. Goncalves
No relevant relationships to disclose
J. Lubinski
No relevant relationships to disclose
C. R. C. Osborne
No relevant relationships to disclose
P. Lardelli
Employment or Leadership Position - PharmaMar
Stock Ownership - Zeltia
J. C. Tercero
Employment or Leadership Position - PharmaMar
Stock Ownership - Zeltia
A. Florez
Employment or Leadership Position - PharmaMar
F. A. Holmes
No relevant relationships to disclose
S. Delaloge
No relevant relationships to disclose